Do cutaneous adverse events significantly affect monoclonal antibody based anti-TNF therapies in IBD patients? A national experience throughout all care levels by the German IBD Study Group (GISG)

Beteiligte Wissenschaftler*innen:
Akad. Rat Dr. Dipl.-Stat. J. Gerß
Dipl.-Stat. M. Eveslage

Studienleitung:
Prof. Dr. med. Daniel Baumgart

Förderung:
Deutsche Morbus Crohn / Colitis ulcerosa Vereinigung DCCV e.V.